
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
According to the CDC, rates of infection for sexually transmitted infections (STIs) among adolescents and young adults are at an all-time high. What steps can clinicians take to overcome barriers to screening and treatment among these high-risk groups - and reduce the risk of lifelong complications that result from untreated STIs?
This online supplement discusses challenges and solutions related to STI screening guidelines, such as:
Read the supplement now!






